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Increasing evidence suggests that phosphorylation may play an important role in the oligomerization, fibrillogenesis, Lewy body (LB)
formation, andneurotoxicity of-synuclein (-syn) in Parkinson disease. Hereinwe demonstrate that-syn is phosphorylated at S87 in
vivo and within LBs. The levels of S87-P are increased in brains of transgenic (TG) models of synucleinopathies and human brains from
Alzheimer disease (AD), LB disease (LBD), andmultiple system atrophy (MSA) patients. Using antibodies against phosphorylated-syn
(S129-P and S87-P), a significant amount of immunoreactivity was detected in the membrane in the LBD, MSA, and AD cases but not in
normalcontrols. Inbrainhomogenates fromdiseasedhumanbrainsandTGanimals, themajorityofS87-P-synwasdetectedinthemembrane
fractions.Abatteryofbiophysicalmethodswereused todissect theeffectofS87phosphorylationon thestructure, aggregation, andmembrane-
binding properties ofmonomeric-syn. These studies demonstrated that phosphorylation at S87 expands the structure of-syn, increases its
conformational flexibility, and blocks its fibrillization in vitro. Furthermore, phosphorylation at S87, but not S129, results in significant reduc-
tionof-synbinding tomembranes. Together, our findings providenovelmechanistic insight into the role of phosphorylation at S87 andS129
in the pathogenesis of synucleinopathies and potential roles of phosphorylation in-syn normal biology.
Introduction
Increasing evidence suggests that phosphorylation may play an
important role in the fibrillogenesis, Lewy body (LB) formation,
and neurotoxicity of -synuclein (-syn) in vivo (Fujiwara et al.,
2002; Anderson et al., 2006). Immunohistochemical and bio-
chemical studies revealed that themajority of-synwithin inclu-
sions isolated from patients with Parkinson disease (PD) and
other synucleinopathies (Kahle et al., 2000; Okochi et al., 2000;
Fujiwara et al., 2002; Takahashi et al., 2003a; Anderson et al.,
2006) is phosphorylated at S129 (S129-P). Proteinaceous inclu-
sions formed in cellular and animal models overexpressing wild-
type (WT) or mutant -syn (Lo Bianco et al., 2002; Takahashi et
al., 2003a; Yamada et al., 2004; Chen and Feany, 2005) can also
be stained with an antibody against S129-P. Although the ki-
nases and phosphatases responsible for regulating -syn phos-
phorylation at S129 in vivo are still not known, a series of in
vitro and cell culture-based studies have identified a number
of kinases, which phosphorylate -syn at S129 and/or S87,
including CKI (S87 and S129) and CKII (S129) (Okochi et al.,
2000) and the G protein-coupled receptor kinases (GRKs 1, 2,
5, and 6, S129) (Pronin et al., 2000), LRRK2 (S129) (Qing et
al., 2009), and Polo-Like Kinases (S129) (Inglis et al., 2009;
Mbefo et al., 2010).
A close comparison of the amino acid sequences of all synucle-
ins from humans and other species shows that the majority of
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potential -syn phosphorylation sites, including Y125, S129,
Y133, and Y136, are highly conserved in all species (supplemental
Fig. 1A, available at www.jneurosci.org as supplemental mate-
rial). Considering all the -syn phosphorylation sites identified
in vivo [S129 (Fujiwara et al., 2002; Chen and Feany, 2005)] and
in vitro [S87 (Okochi et al., 2000; Kim et al., 2006), S129 (Okochi
et al., 2000; Pronin et al., 2000; Fujiwara et al., 2002; Takahashi et
al., 2003a; Chen and Feany, 2005; Kim et al., 2006), Y125, Y133,
and Y136 (Ellis et al., 2001; Nakamura et al., 2001; Ahn et al.,
2002; Negro et al., 2002; Takahashi et al., 2003b)], it is striking
that only S87 lies in the hydrophobic non-amyloid component
(NAC) region of -syn, which is essential for -syn aggregation
and fibrillogenesis (El-Agnaf et al., 1998). S87 is one of the few
residues and phosphorylation sites that distinguish the human
-syn sequence from that of mouse and rat -syn (supplemental
Fig. 1B, available at www.jneurosci.org as supplemental mate-
rial). It is noteworthy that the sequences of mouse and rat -syn
contains the PD-associated mutation A53T, but do not develop
PD pathology and symptoms. Therefore, we hypothesized that
S87might be an important contributor to PD-like pathology and
symptoms induced in human, but not mouse and rat -syn,
where this residue is absent.
These observations prompted us to investigate the physiolog-
ical relevance of S87 phosphorylation in vivo and its conse-
quences on the structural and aggregation properties of -syn in
vitro. Toward these goals, we generated an antibody against
phosphor-S87 and used it to investigate the presence of S87-P in
LBs and compare the levels of S87-P -syn in the brains of trans-
genic (TG) models of -synucleinopathies as well as in human
Alzheimer disease (AD), Lewy body disease (LBD), and multiple
system atrophy (MSA) brains. To examine further the role of S87
phosphorylation in modulating the structural, aggregation, and
membrane-binding properties of -syn, we carried out a thor-
ough comparative characterization of the phosphomimic S87E
and the in vitro phosphorylated S87-P -syn, as well as the S87A
and WT -syn using an array of biochemical and biophysical
methods. Our findings and their implications for the under-
standing of the normal biology of -syn and its role in the patho-
genesis of PD are discussed.
Materials andMethods
Validation of the anti-S87P antibody in vivo
Plasmid construction and production of recombinant AAV2/6 viral vectors.
A single-nucleotide mutation coding for S87D was introduced into the
cDNA of human -syn already containing the A30P pathogenic muta-
tion using the QuickChange Site-Directed Mutagenesis kit (Stratagene).
Beforehand, theA30P-syn cDNAhadbeen cloned into theAAV-CMV-
MCS backbone (Stratagene). The S129A mutation had been generated
previously (Azeredo da Silveira et al., 2009). For the S87D variant, the
mutagenesis primers were: sense 5-GGAGGGAGCAGGGGACATTG-
CAGCAGCCAC-3 and antisense 5-GTGGCTGCTGCAATGTCC-
CCTGCTCCCTCC-3. Production and titration of the recombinant
pseudotyped AAV2/6 vectors (serotype 2 genome/serotype 6 capsid)
were performed as previously described by Azeredo da Silveira et al.
(2009).
Stereotaxic injections. Male Wistar rats (Charles River Laboratories),
weighing 180–200 g at the time of surgery were maintained under 12 h
light/dark cycle, with ad libitum access to food and water, in accordance
with the Swiss legislation and the European Community council direc-
tive (86/609/EEC) for the care and use of laboratory animals. Stereotaxic
injections were performed under xylazine/ketamine anesthesia. Animals
were placed in the stereotaxic frame (David Kopf Instruments) and re-
ceived a unilateral intranigral injection of 2 l of viral suspension, cor-
responding to a viral load of 2.5 107 transducing units. Injections were
performed in the right brain hemisphere at a speed of 0.2 l/min con-
trolled by an automatic pump (CMAMicrodialysis), using a 10l Ham-
ilton syringe connected to a 34-gauge blunt-tip needle. The needle was
left in place for an additional 5 min before being slowly withdrawn.
Stereotaxic coordinates for virus injections above the substantia nigra
pars compacta were as follows: anteroposterior (AP): 5.2 mm, lateral
(L):2.0 mm; dorsoventral (DV):7.8 from the skull surface; with the
incisor bar at 0.0 mm, according to the rat stereotaxic atlas by Paxinos
and Watson (1986). To examine the in vivo specificity of our antibody
against S87-P, animals injected with AAV2/6--syn A30P S129A viruses
were sacrificed 13 weeks postinjection and transcardially perfused with
4% paraformaldehyde (PFA, Fluka-Sigma). Brains were removed, post-
fixed overnight in PFA 4%, and then transferred into 30% sucrose. Coro-
nal sections (25 m thick) were cut at 20°C with a microtome
(SM2400; Leica) and slices were stored at20°C in antifreeze medium.
Samples and tissue processing
Analysis of -syn phosphorylation was performed with postmortem hu-
man temporal cortex samples and with the brains of -syn TGmice. The
human samples were obtained from the Alzheimer Disease Research
Center at the University of San Diego. A total of 21 cases were included,
of which sixwere nondemented controls, six were diagnosed as AD, six as
LBD, and three as MSA. In all cases the brains were processed within 8 h
after death. Brains were divided sagittally, the right hemibrain was seri-
ally sectioned and preserved at70°C, and the left hemibrain was fixed
in formaldehyde. For neuropathological diagnosis, paraffin sections
from cortical and subcortical brain regions were stained with H&E, and
thiofavine-S, and immunostained with antibodies against ubiquitin and
-syn.
Three different -syn TGmouse lines were used for this study: PDGF
-syn WT (Rockenstein et al., 2002), mThy1 -syn WT (van der Putten
et al., 2000), and MBP -syn WT (Shults et al., 2005). Control experi-
ments were performed with age-matched non-TG littermates. The
PDGF -syn WT TG mice display abundant -syn accumulation in the
neocortex and limbic system and mimics some aspects of diffuse LBD,
the mThy1-syn WT shows more abundant accumulation of -syn in
subcortical regions with motor defects and mimics some aspects of PD.
The MBP -syn TG line accumulates syn in oligodendrocytes in cortical
and subcortical regions andmimics some aspects of MSA. In accordance
with National Institutes of Health (NIH) guidelines for the humane
treatment of animals, mice were killed (at 6 months of age) by deep
anesthesia with chloral hydrate. Brains were removed and divided sagit-
tally. One hemibrain was postfixed in phosphate-buffered 4% parafor-
maldehyde, pH 7.4, at 4°C for 48 h and sectioned at 40 m with a
Vibratome 2000 (Leica), while the other hemibrain was snap frozen and
stored at70°C for Western blot analysis.
Immunocytochemistry
S87-P in transgenic mice.To investigate the distribution of the phosphor-
ylated -syn epitopes brains from non-TG and TG mice, serially-
sectioned, free-floating, blind-coded vibratome sections were incubated
overnight at 4°C with either the mouse monoclonal antibody against
-syn (syn-1, 1:500, Transduction Laboratories), rabbit polyclonal anti-
human -syn-specific antibody (Millipore Bioscience Research Re-
agents, 1:500), mouse monoclonal against S129-P -syn and the rabbit
polyclonal against S87-P -syn, as described previously (Masliah et al.,
2000). Incubation with the primary antibody was followed by anti-
mouse IgG or goat anti-rabbit IgG (1:100, Vector) followed by avidin
D-HRP and DAB. Sections were analyzed with an Olympus bright field
video microscope. For each case, three sections were analyzed and the
results were averaged and expressed as mean pixel intensity.
Analysis of injected rat brains. For Immunofluorescence, slices were
washed overnight in PBS and incubated 30 min in H2O2 for 30 min at
room temperature, then blocked in a solution of 5% bovine serum albu-
min (BSA, Sigma), 10% normal goat serum (NGS, Vector Laboratories),
and 0.1% Triton X-100 (AppliChem) in PBS, during 2 h at room tem-
perature. Slices were then incubated overnight at 4°C with the primary
anti-tyrosine hydroxylase (1:500; AB152; Millipore) and anti-Human
-syn (1:500; LB509, Zymed Laboratories) antibodies in blocking buffer
and subsequently incubated for 2 h at room temperature with secondary
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antibodies conjugated to Alexa Fluor-488 or Alexa Fluor-568 (1:1000;
Invitrogen AG). Slices were finally washed and mounted on glass slides
using DABCO mounting solution (Sigma-Aldrich). For the enzymatic
revelation, slices were washed overnight in PBS and incubated in phenyl-
hydrazine (Sigma-Aldrich) for 1 h at 37°C and blocked in a solution of
5% BSA, 10% NGS, and 0.1% Triton X-100 in PBS, during 2 h at room
temperature. Slices were incubated overnight at 4°C with the primary
antibody anti-P Ser 87 (1:100) and then incubated for 2 h with the bio-
tinylated secondary antibody (1:200; Vector Laboratories) followed by
incubation in avidin–biotin–peroxidase complex (Vector Laboratories)
for 30min at room temperature. Sections were finally revealed withDAB
andmounted on glass slides withMerckoglas mountingmedium (Merck).
Double labeling and confocal microscopy. To determine the colocaliza-
tion between -syn-immunolabeled neurons and CK1, 40-m-thick vi-
bratome sections from -syn TG mice were immunolabeled with the
rabbit polyclonal antibodies against -syn (Millipore Bioscience Re-
search Reagents, affinity purified polyclonal, 1:500) (Masliah and Rock-
enstein, 2000) and CK1 (C-18; Santa Cruz Biotechnology, 1:100). The
CK1-positive cells were detected with the Tyramide Signal Ampli-
fication-Direct (Red) system (1:100, NEN Life Sciences), whereas -syn
immunoreactive was detected with the goat anti-rabbit fluorescein iso-
thiocyanate antibody (Vector, 1:75). This systemallows the simultaneous
detection of signals from antibodies from the same species. All sections
were processed under the same standardized conditions. The immuno-
labeled blind-coded sectionswere serially imagedwith the laser-scanning
confocal microscope (MRC1024, Bio-Rad). For each mouse, a total of
three sections were analyzed and for each section, four fields in the fron-
tal cortex and hippocampus were examined.
Detection of S87-P in Lewy bodies. Lewy body enrichment was con-
ducted as previously described (Gai et al., 2000). Fresh frozen brain
tissues were from three diffuse Lewy body disease cases [sex/age at death/
postmortem interval (h): m/80/6, m/74/24, f/81/12]. Gray matter was
dissected temporal cortex comprising the superior, middle, inferior, and
fusiform gyri from a 1-cm-thick coronal slice at the level of caudal amyg-
daloid, and homogenized in four volumes of homogenization buffer
(HB; 0.32 M sucrose, 50mMTris-HCl at pH 7.4, 5mM EDTA, leupeptin 1
mg/ml, pepstatin 1 mg/ml, phenylmethylsulfonyl fluoride 17.4 mg/ml),
and homogenized in a Dounce homogenizer (Wheaton) by 10 strokes of
pestle A and 10 strokes of pestle B. The homogenate was filtered through
glass wool and centrifuged for 10min at 1000 g. The pellet was adjusted
to 6 ml with HB and Percoll to 14% (v/v) of Percoll concentration. The
suspension was overlaid on 2.4 ml of 35% Percoll (v/v in HB) and cen-
trifuged for 30 min at 35,000 g. The material between the sample-35%
Percoll interface was collected andwashed once in TBS (50mMTris–HCl
buffered saline pH 7.4 and protease inhibitors) by centrifugation for 10
min at 4000 g. The above procedures were conducted either on ice or
at 4°C. The pellet was resuspended in 10 volumes of TBS and smeared
onto gelatin-coated slides and air-dried at room temperature.
The smears were fixed for 10 min with 2% paraformaldehyde with
0.2%picric acid in PBS, followedby 3 5minwasheswithTBS-azide (20
mM Tris-HCl, 0.15M NaCl, 0.1% sodium azide, pH 7.4), blocked for 60
minwith 20%normal horse serum (NHS) in TBS-azide, incubated over-
night with primary antibody pairs constituted in 1% NHS TBS-azide.
Primary antibodies were affinity-purified sheep anti--syn (Gai et al.,
1999) used at 5 g/ml, affinity purified rabbit anti-S87-P -syn, and
mouse monoclonal11A5 anti-pS129 -syn (Anderson et al., 2006).
Omitting primary antibodies were used as negative controls. Following
3 5minwashes with TBS-azide, the smears were incubated for 1 hwith
Alexa 594 or Alexa 488 conjugated donkey anti-sheep, donkey anti-
rabbit, or donkey anti-mouse (Invitrogen). The smears were washed 3
5minwashes with TBS-azide, and coverslipped with 20l of Vectashield
mounting medium, sealed with nail polish, and examined using a Leica
TCS SP5 Spectral Confocal Microscope.
Cloning, expression, and purification of -syn variants
The S129E, S129A, S87A, and S87E -syn mutants were generated using
site-directedmutagenesis employing complementary internalmutagenic
primers and two-step PCR. All cDNA sequences were confirmed by se-
quencing. All proteins used in these studies were expressed as previously
described (Kessler et al., 2003), except those used for nuclear magnetic
resonance (NMR) studies (see below). Cell lysis (Microfluidics Corpora-
tionM110-EHI) was followed by ammonium sulfate precipitation [30%
(w/v) solution], anion exchange chromatography (GE Healthcare Q
Sepharose) in 10mMTris-HCl/1mMEDTA/pH 8.0, and cation exchange
chromatography (GEHealthcare S Sepharose) in 10mM sodium acetate/
1 mM EDTA/pH 4.0. The final homogeneity of each preparation was
determined by densitometric analysis of Coomassie-stained SDS-PAGE
gel scans (NIH Image 1.61/ppc program). Purified preparations were
lyophilized from ammonium bicarbonate buffer (100 mM; buffer ex-
change achieved by GE Healthcare G25 chromatography) and stored at
20°C until use. For the NMR studies, expression and purification of
unlabeled and 15N-labeled-synwere performed as described (Eliezer et
al., 2001;Hoyer et al., 2002). To enable attachment of a spin label, a single
Cys was introduced into -syn at position 18 (A18C). The nitroxide spin
label chosen for reaction with the Cys-containing mutant was MTSL
(1-oxy-2, 2, 5, 5-tetramethyl-D-pyrroline-3-methyl)-methanethiosul-
fonate (Toronto Research Chemicals). MTSL has been shown previously
to efficiently react with -syn Cys mutants and the reaction was carried
out as described previously (Bertoncini et al., 2005).
In vitro phosphorylation and dephosphorylation assays
WT or mutant -syn was phosphorylated by CK1delta (specific activity
2,000,000 U/mg; NEB) at concentrations of 1.446 mg/ml (unless other-
wise stated), in the presence of 1.09 mM ATP (Sigma), 1 reaction solu-
tion supplied with the enzyme and 1200U of CK1/145 g of -syn. The
phosphorylation reaction was incubated at 30°C for the stated time
points, and the reaction was stopped with EDTA disodium salt (5 mM
final concentration; Axon Lab). The progress of the reaction was moni-
tored by RP-HPLC and mass spectrometry (Wilkins et al., 1999). -Syn
dephosphorylation was performed with calf intestinal alkaline phospha-
tase (CIAP) (Promega). Briefly,-syn previously phosphorylated at both
S87 and S129 by CK1 was incubated 1 h at 37°C with CIAP at the con-
centration of 200 U/l (2000U/g of protein) in 1 CIAP buffer. The
reaction was stopped by adding the loading buffer, and the progress of
the phosphorylation reaction was monitored by Western blot using an-
tibodies against S87-P and S129-P.
Fibrillization studies
To probe the effect of CK1-mediated phosphorylation on the aggrega-
tion of -syn, 100 M WT and mutant -syn were first phosphorylated
and then subjected to fibrillization conditions, at 37°C with continuous
shaking for the indicated time points. The unphosphorylated controls
were treated under the same conditions as the phosphorylated samples,
but CK1 was not added to them. The extent of fibril formation was
monitored by ThT fluorescence assay and by determining the amount of
soluble monomeric and oligomeric -syn in solution at indicated time
point during the aggregation process (Paleologou et al., 2008).
Gel electrophoresis (SDS-PAGE) and immunoblotting
-Syn samples were diluted in loading buffer and separated on 12% SDS
1 mm gel. Gels were stained with Simply Blue Safe stain (Invitrogen) or
silver stained (Invitrogen) according to manufacturer’s instructions. For
Western blots, membranes were probed with the primary antibody
[mouse monoclonal anti--syn (121–125) (211) at a dilution of 1:500
(Santa Cruz Biotechnology) or mouse anti--syn (15–123) at a dilution
of 1:1000 (BD Transduction), or mouse monoclonal anti-S129-P -syn
at a dilution of 1:5000 (Wako), or rabbit polyclonal anti-S87-P  -syn at
a dilution of 1:100] at room temperature (RT) for 1–2 h. After incubation
with the secondary antibody (i.e., goat anti-mouse ALEXA Fluor 680)
protected from the light at RT, for 1 h and washing with PBST (4), the
immunoblots were scanned in a Li-COR scanner at a wavelength of 700
nm. TheWestern blot analysis for brain homogenates was carried out as
follows. Brain homogenates that include the frontal cortex and the stri-
atum were separated by ultracentrifugation as previously described into
cytosolic and membrane fractions (Masliah and Rockenstein, 2000).
Samples from both cytosolic and membrane fractions were separated on
12% or 4–12% SDS-PAGE gels (NuPAGE, Invitrogen) and transferred
onto 0.22M nitrocellulose membranes (Schleicher & Schuell) using 1
3-[cyclohexylamino]-1-propaneosulfonic acid (CAPS) transfer buffer
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containing 20% methanol. Membranes were
blocked with 3% milk in PBS containing 0.1%
Tween-20 (Sigma) (PBS-T), followed by incu-
bation in primary antibody (1:1000) in PBS-T
overnight at 4°C. The primary antibodies used
were as follows: rabbit polyclonal against total
-syn (Millipore Bioscience Research Re-
agents); mouse monoclonal against S129-P
-syn (courtesy of Dr. T. Iwatsubo, University
of Tokyo, Tokyo, Japan), rabbit polyclonal
against S87-P -syn and mouse monoclonal
against -actin (Millipore Bioscience Research
Reagents). Membranes were further incubated
with goat anti-mouse or anti-rabbit IgG sec-
ondary antibodies conjugated to horseradish
peroxidase (1:5000, American Qualex) and
visualized by enhanced chemiluminescence
(ECL, NEN Life Sciences) and exposed to film.
For determinations of levels of immunoreac-
tivity, ECL-treated membranes were analyzed
in the VersaDoc imaging system (Bio-Rad) us-
ing the Quantity One software (Bio-Rad).
Preparation of large unilamellar vesicles
and small unilamellar vesicles and
-syn-liposome complexes
1-Palmitoyl-2-oleoyl-sn-glycero-3-[phospho-rac-
(1-glycerol)] (sodium salt, POPG; Avanti Polar
Lipids) was purchased in chloroform which
was removed by evaporation and lyophiliza-
tion. The residual phospholipid was hydrated
with 50 mM HEPES (Fluka), 150 mM NaCl
(Fluka), pH 7.4 solution, giving rise to a phos-
pholipid suspension of 10 mg/ml. To increase
the efficiency of large unilamellar vesicles for-
mation, 10 cycles of freezing in dry ice and
thawing at 37°C water bath were carried out.
Small unilamellar vesicles were prepared by ex-
Figure 1. Specificity of anti-S87-P antibody.A, WT andmutant-syn phosphorylated for 24 hwere separated on a 12%SDS gel and probedwith anti--syn (211, 1:500), anti-S129-P (1:5000),
or anti-S87-P (1:100)-syn antibodies. B, S87-P and S129-P antibodies failed to detect phosphorylated forms of-syn treated with calf intestinal alkaline phosphatase. C–N, Virus mediated-
overexpression of human -syn A30P S129A (C–H ) and human -syn A30P S87D S129A (I–N ) in the rat substantia nigra. The staining for human -syn (LB509) colocalized with tyrosine
hydroxylase (TH) staining (C,D, I, J ) in the injected side (E,K ), butwas absent in the noninjected side (F, L). The staining for S87-Pwas restricted to the side injectedwith the virus coding for human
-syn A30P S129A (G), whereas no staining could be detected on the side injected with the mutant-syn form S87D (M ). Noninjected sides also appeared negative (H, N ). Scale bar, 500m.
Figure 2. Comparison of the levels of phosphorylated-syn immunoreactivity by immunoblot in human brains from control,
AD, LBD, and MSA cases. Samples from the frontal cortex were divided into cytosolic and particulate fractions and analyzed by
Western blot with antibodies against total and phosphorylated -syn. A, B, Cytosolic and particulate fractions probed with an
antibody against total-syn. Native-syn is identified at 14 kDa. Compared to controls, in LBD cases therewas increased levels of
native and aggregated-syn above 28 kDa preferentially in the membrane fraction. C, D, S87-P-syn was identified as a single
band at 14 kDa in themembrane fraction. The intensity of this band was greater in LBD, MSA, and AD cases compared to controls.
E, F, The native S129-P-syn was identified as a single band at 14 kDa and oligomerized-syn was identified as multiple bands
ranging from 28 kDa to 98 kDa. S129-P-synwas only identified in themembrane fraction andwasmost abundant in LBD cases.
G,H, I, Quantitative analysis of brain homogenate from 21 AD, LBD, MSA, and control cases including the representative samples
shown inA–F. Statistical analyses are performedusing a one-wayANOVA followedby post hocDunnet’s test. *p 0.05 compared
with control values.
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trusion through a 100 nm polycarbonatemembrane (Avestin) according
to manufacturer’s instructions. The small unilamellar vesicles were
stored at 4°C and used within 3–5 d. The appropriate amount and vol-
ume of -syn in PBS or sodium phosphate, pH 7.5, was mixed with the
appropriate volume of POPG to generate a mass ratio of  -syn:POPG of
1:20. The -syn-liposome complex was incubated for 2 h at RT before
circular dichroism (CD) spectroscopy.
Circular dichroism
The average secondary structure of monomeric -syn in the presence
and absence of POPG (Avanti Polar Lipids) vesicles was determined
by circular dichroism (CD) spectroscopy using a Jasco 810 Spectrom-
eter. The Far UV-CD spectra (190–250 nm, integration time of 2 s for
0.2 nm) were collected at RT in a 1 mm path length quartz cuvette
containing 0.1 mg/mL of -syn in PBS or sodium phosphate buffer
and vesicles were prepared as described by Paleologou et al. (2008).
Transmission electron microscopy
For electron microscopy (EM) studies, WT or mutant -syn samples
were deposited on Formvar-coated 200mesh copper grids (ElectronMi-
croscopy Sciences) at a concentration of 25 M. Grids were washed with
two drops of water and stained with two drops of freshly prepared 0.75%
(w/v) uranyl acetate (Electron Microscopy Sciences). Specimens were
inspected on a Philip CMX 10 electron microscope, operated at 100 kV.
Digitized photographs were recorded with a slow scan CCD camera
(Gatan, Model 679).
Nuclear magnetic resonance
NMR samples of free -syn contained  0.1 mM 15N-labeled WT or
mutant-syn in 90%H2O/10%D2O, 50mM phosphate buffer at pH 7.4,
100 mM NaCl. NMR experiments were acquired on Bruker Avance 600
and 700 MHz NMR spectrometers. The temperature was set to 15°C.
NMR data were processed and analyzed using NMRPipe (Delaglio et al.,
1995) and Sparky 3 (T. D. Goddard and D. G. Kneller, SPARKY 3, Uni-
versity of California, San Francisco, San Francisco, CA) and NMRView
(Johnson and Blevins, 1994). Spectra were referenced indirectly to DSS
and ammonia using the known chemical shift of water (Wishart et al.,
1995). Tentative assignments for the spectra of mutant and phosphory-
lated proteins were obtained by transferring each previously assigned
cross peak in the 1H-15N heteronuclear single quantum coherence
(HSQC) spectrum of the WT protein to the nearest unassigned cross
peak in each new spectrum. Subsequently, they were verified by three-
dimensional HNHA and three-dimensional NOESY-HSQC spectra (Bax
and Grzesiek, 1993). 3J(HN,H) scalar couplings were measured using
intensity modulated HSQC experiments (Permi et al., 2000). 15N R1
spin relaxation rates were measured with a pulse sequence based on
Farrow et al. (Farrow et al., 1994) on a Bruker Avance 600 MHz spec-
trometer. Relaxation delays were set to 8, 48, 64, 128, and 184 ms. The
spin lock frequency was 2.5 kHz. Relaxation times were calculated by
fitting an exponential function to the decaying signal integrals. Steady-
state heteronuclear 15N[1H]-NOE values are reported as the ratio of
peak heights in paired spectra collectedwith andwithout an initial period
(4 s) of proton saturation during the 5-s recycle delay. Pulse field gradient
NMR experiments were acquired on unlabeled WT and mutant -syn
(concentration of 200 M) dissolved in 99.9% D2O, 50 mM phosphate
buffer pH 7.4 and containing dioxane (concentration 20 mM) as an
internal radius standard and viscosity probe (Wilkins et al., 1999).
Twenty one-dimensional 1H spectra were collected as a function of gra-
dient amplitude employing the PG-SLED sequence (Jones et al., 1997;
Wilkins et al., 1999). Each experiment was repeated at least two times.
The gradient strength was increased from 1.69 to 33.72 Gauss/cm, in a
Figure 3. Analysis of the colocalization of S87-P and -syn in LBs isolated from fresh brain of DLB cases (A–K ). Immunostaining anti-S87-P in conjunction with sheep anti--syn antibody
showed a colocalization of the two forms of-syn in a mature (A–C) and a less mature cortical LB (D–F ). G–I correspond to control staining in which anti-S87-P antibody has been omitted, no
labeling for S87-Pwasdetected in the Lewybody. JandK illustrate a fluorescence intensity analysis for-syn (red line), S87-P (green), andDNA (blue) labelings across a Lewybody, indicatingagood
colocalization between total-syn and pS87-syn reactivities. Scale bars: (in B, E,H ) A–J, 10m. S87-P is enriched in SDS/Urea soluble fractions of synucleinopathies (L–O). Samples from the
temporal cortexwere separated by high-speed centrifugation at 18,000 g for 30min, and pellet containing vesicles and particulatematerial were future solubilized in SDS/Urea. Increased S87-P
-syn reactivity was detected in SDS/Urea soluble fraction M compared to buffer soluble fraction L. In contrast, total -syn reactivity was more prominent in buffer soluble fraction N than in
SDS/Urea soluble fraction O.
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linear manner. Signals corresponding to the aliphatic region of the 1H
spectra (3.3–0.5 ppm) were integrated and diffusion data (signal inten-
sity versus gradient strength) were fitted to Gaussian functions using
XWINNMR (Bruker Instruments). Stokes radii of -syn were calculated
from the apparent diffusion coefficients of -syn and dioxane, and the
known Stokes radius of dioxane (Jones et al., 1997). Errors in stokes radii
estimated from repeat measurements are about 0.5 Å.
For NMR studies of micelle-bound -syn, lyophilized protein was
dissolved in sample buffer (100 mM NaCl, 10 mM Na2HPO4, pH 7.4 in
90%/10%H2O/D2O) with 40 mM deuterated SDS (Cambridge Isotope).
Spectra were recorded on either Varian INOVA600MHz (Weill Cornell,
New York, NY) or a Bruker Avance 800 MHz (New York Structural
Biology Center, New York, NY) spectrometers at sample temperature
of 40°C. Two-dimensional and three-dimensional double and triple res-
onance data, including HSQC, HNCACB, CBCACONH, HNCO,
HNCACO, and HSQC-NOESY-HSQC, were collected using standard
pulse sequences. A mixing time of 150 ms was used for the NOESY
experiment. Typical spectral widths were 10, 20, 8, and 53 PPM in the
proton, nitrogen, CO, and C dimensions. Data were processed using
NMRPipe (Delaglio et al., 1995) and analyzed usingNMRView (Johnson
and Blevins, 1994).
Results
Characterization of-syn phosphorylation in TGmodels of
synucleinopathies and human brain from AD, LBD, andMSA
patients
To determine the physiological and pathological relevance of S87
phosphorylation, we generated a rabbit polyclonal antibody,
anti-S87-P, against a synthetic peptide that corresponds to amino
acid residues 81–93 of human -syn, with S87 being phosphory-
lated. Figure 1A demonstrate that our anti-S87-P antibody spe-
cifically detects serine 87 phosphorylated forms (S87-P) of-syn,
and reveals the absence of immunoreactivity against either un-
phosphorylated, S129A, or S129-P -syn. To rule out the possi-
bility that the lack of immunoreactivity of S87A is due to a loss of
the epitope rather than lack of phosphorylation, the specificity of
the antibody was verified by probing its immunoreactivity to-
ward diphosphorylated -syn (S87-P/S129-P) after phosphatase
(CIAP) treatment. Phosphatase treatment resulted in the loss of
immunoreactivity toward both anti-S87-P and anti-S129-P anti-
bodies (Fig. 1B), consistent with the loss of the phosphate group
on both residues, thus providing further verification of the spec-
ificity of both antibodies.
To probe the specificity of our S87-P antibody and determine
whether phosphorylation at this residue occurs in vivo, we char-
acterized the level of S87-P in slices from rat brains injected on
one side with an AAV2/6 viral vector overexpressing the S129A
variant of -syn A30P (Fig. 1C–H) (n 3). As a control, we also
examined tissues from rat brains injected a mutant form of the
same protein, in which phosphorylation at S87 was blocked by a
serine to aspartate substitution at position 87 (S87D/S129A-
A30P) (Fig. 1 I–N) (n  3). In both cases, the uninjected side
served as an additional control to assess the level of background
signal due to nonspecific interactions and antibody cross-
reactivity with other proteins. We detected a strong staining
against human A30P -syn in the injected substantia nigra (Fig.
1E,K) compared to the noninjected side (Fig. 1F,L). However,
anti-S87-P staining was exclusively detected in the substantia
nigra overexpressing human S129A-syn (Fig. 1G) and no label-
ing was detectable, neither in the noninjected side (Fig. 1H,N)
nor in the substantia nigra overexpressing the S87D/S129A
mutant (Fig. 1M). These findings demonstrate conclusively
that phosphorylation at serine 87 does occur in vivo, at least
under conditions of increased -syn expression [correspond-
ing to an approximate doubling of the total -syn level in
nigral tissue extracts (Azeredo da Silveira et al., 2009)] and
validate the specificity of our antibody on brain tissue. How-
ever, it is not possible to determine the overexpression levels
in individual neurons.
-Syn in LBs is phosphorylated at S87-P and S87-P levels are
increased in human brains from AD, LBD, andMSA patients
Having established the specificity of the antibody, anti-S87-P,
together with anti--syn and anti-S129-P antibodies, was tested
in human brain (frontal cortex) homogenates from control, AD,
LBD, and MSA cases. Immunoblot analysis of cortical samples,
from control or diseased human brains, showed a native -syn
band at 14 kDa in the cytosolic fractions (Fig. 2A), which was
significantly increased in the AD, LBD, andMSA cases relative to
the control (Fig. 2A,G). In the membrane fractions increased
-syn levels are detected in the LBD and MSA cases, with higher
molecular weigh species being present in the LBD cases only (Fig.
2B,G). Anti-S87-P antibody detected a weak band at 14 kDa in
the control cases. This band became more pronounced in the
Figure 4. Comparison of the levels of phosphorylated -syn immunoreactivity by im-
munoblot in brains of-synmodels of LBD. Samples from the neocortex were divided into
cytosolic and particulate fractions and analyzed by Western blot with antibodies against
total and phosphorylated-syn. The PDGF--syn express moderate levels of-syn in the
neocortex and hippocampus, the thy1--syn expresses high levels of-syn in cortex and
subcortex, the MBP--syn accumulates syn in oligos and is a model for aspects of MSA.
A, B, Cytosolic and particulate fractions probed with an antibody against total -syn.
Native -syn is identified at 14 kDa. In the TG mice there is an increase in native -syn
compared to non-TG. Compared to non-TG, in thy1--syn cases there was increased
accumulation of-syn aggregates above 28 kDa preferentially in the membrane fraction.
C and D, S87-P-syn was identified as a single band at 14 kDa. This band was exclusive to
the membrane fraction and detected only in the TG mice cases. E, F, The native S129-P
-syn was identified as a single band at 14 kDa and oligomerized-syn was identified as
multiple bands ranging from 28 kDa to 98 kDa. The aggregated S129-P-syn identified in
the -syn TG mice was more abundant in the membrane fraction. The native form was
more abundant in the cytosolic fraction.
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diseased brains notably in the LBD cases
(Fig. 2D,H), where it was accompanied
by a weaker band at around 17 kDa. The
antibody against S129-P detected a band
at 14 kDa as well as higher MW bands
(Fig. 2E,F,I). With both antibodies
against phosphorylated -syn most of the
immunoreactivity was detected in the
membrane fractions in the LBD andMSA
cases but not in the controls and AD cases
(Fig. 2C–F). Several -syn immunoreac-
tive bands at molecular weights of 38 kDa
and higher were detected in the control
samples from LBD cases. These bands
were more abundant in the membrane
fractions and showed clear immunoreac-
tivity toward the anti-S129-P, but at
best weak reactivity to the anti-S87-P
antibody.
To further investigate the pathological
relevance of S87 phosphorylation, we as-
sessed S87-P levels in Lewy body samples
from three diffuse Lewy body (DLB)
cases. Lewy bodies were intensely labeled
by the sheep anti--syn antibody. There-
fore, the signal gain was set low (50% of
S87-P -syn signal) to show characteristic
homogenous and concentric patterns,
with little background or neuropile label-
ing (Fig. 3, left column). The S87-P -syn
immunoreactivity was less intense but
readily detected in all Lewy bodies (500
Lewy bodies were analyzed by confocal
microscopy). The S87-P -syn labeling appeared smooth within
Lewy bodies (Fig. 3B,E). In addition, granular S87-P-syn label-
ings of 0.2–0.5m size were also detected, more obvious in Lewy
body periphery, neural processes, and neuropil (Fig. 3A,D). No
such labeling was seen when anti-S87-P -syn antibody was
omitted. These granular labelings may be complexes or cellular
particles containing more concentrated S87-P -syn. Figure 3, J
and K, illustrates the relative intensities for -syn (red line),
S87-P -syn (green), and DNA (blue) labelings across a Lewy
body. However, it must be noted that fluorescence intensity de-
pends on many factors, including the dye used, the affinity of
each antibody for its epitope, the accessibility of the epitope, etc.
The localization of S87-P-syn in Lewy bodies suggests it is an
integrated part of the inclusions. We further examined whether
S87-P -syn is enriched in buffer insoluble fractions in brains of
synucleinopathies and Alzheimer’s disease. The buffer insoluble
fractions contained numerous Lewy bodies and glial inclusions
and were further solubilized in 5%SDS/Urea. As shown in Figure
3L–O, S87-P -syn reactivity was more prominent in 5%SDS/
Urea fraction, compared to total -syn reactivity. Figure 3M
demonstrates that the level of S87-P in these fractions is higher in
diseased brains relative to control cases.
The levels of S87-P are increased in brains of TGmodels
of synucleinopathies
To further assess whether S87 phosphorylation is a pathological
event, we assessed its levels in brain homogenates fromTGmouse
experimental models of PD/LBD and MSA (Fig. 4). As expected
the highest levels of -syn expression were observed in the
mThy1 -syn TG mice followed by the PDGF -syn and the
MBP--syn TG both in the cytosolic (Fig. 4A,C,E) and mem-
brane fractions (Fig. 4B,D,F). Bands reflecting monomers (at 14
kDa) and the oligomers (at 38–62 kDa) were detected. Consis-
tent with the finding in the human brain homogenates, antibod-
ies against S87-P detected a band at 14 kDa, which were
significantly more abundant in the membrane fraction of the
mThy1 -syn TGmice (Fig. 4D). With antibody against S129-P,
a strong 14 kDa band was detected in the cytosolic fraction of
both themThy1-syn andMBP-synTGmice (Fig. 4E). S129-P
-synwas detected at 14 and 42 kDa in themembrane fractions of
the -syn TG mice (Fig. 4F). Consistent with the Western blots,
immunocytochemical analysis with the antibody against total
-syn showed immunoreactivity in the neuropil corresponding
to nerve terminals in the non-TG mice (Fig. 5A). In the PDGF
andmThy1--syn TGmice abundant accumulation of-synwas
detected in the neuronal cell bodies, whereas in MBP -syn TG
mice immunoreactivity was associated with oligodendrocytes
(Fig. 5B–D). With S129-P antibody abundant -syn immunore-
activity was detected in the three lines of -syn TG mice (Fig.
5E–H). With the S87-P antibody abundant immunoreactivity
was observed in the neuronal cell bodies of the mThy1--syn TG
(but not in the PDGF--syn) mice and in the inclusions in the
oligodendrocytes in the MBP--syn TG mice (Fig. 5K,L).
S87-P colocalization with CK1
Among the various kinases reported to phosphorylate -syn in
vitro, CK1 and the dual specificity tyrosine regulated kinase 1A
(Dyrk1A) are the only two that phosphorylate -syn at S87. To
determine the colocalization between S87-P immuno-
labeled-neurons and CK1, 40-m-thick vibratome sections from
Figure 5. Patterns of phosphorylated -syn immunoreactivity in brains of -syn models of LBD. Vibratome sections were
immunostainedwith antibodies against total andphosphorylated-syn.A–D, The PDGF--syn expressmoderate levels of-syn
in the neocortex and hippocampus, the thy1--syn expresses high levels of-syn in cortex and subcortex, and the MBP--syn
accumulates syn in oligos and is amodel for aspects ofMSA. Compared to non-TG in-syn TGmice there is abundant accumulation
of total -syn and the most abundant is in Thy1--syn mice. In MBP--syn accumulation is in oligos. E–H, S129-P -syn
accumulates in neurons in PDFG--syn andThy1--synneurons and inMBP--syn TGmice in oligos (Abeliovich et al., 2000). I–L,
S87-P-syn was found in some neurons in Thy1--syn and in MBP--syn cases but not in PDGF--syn.
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the temporal cortex of-syn TGmice and LBD/PD patients were
immunolabeled with the antibodies against S87-P and CK1. Fig-
ure 6 demonstrates a great degree of colocalization of S87-P and
CK1 in neuronal inclusions in Tg mice (Fig. 6A) and in LB-like
structures in LBD/PD diseased brains (Fig. 6B), consistent with
in vitro observations and suggesting that CK1 may by directly
involved in modulating -syn phosphorylation in vivo. These
findings are consistent with previous cell culture studies impli-
cating CK1 in the phosphorylation of -syn at S129 and S87
(Okochi et al., 2000).
Serine3glutamate substitution or phosphorylation at S87
inhibits the fibrillization ofWT andmutant (S129A and
S129E)-syn
Having verified the pathological relevance of S87 phosphoryla-
tion, we sought to understand the role of S87 phosphorylation in
modulating the structure and aggregation properties of -syn.
Toward this goal, we compared the structural, oligomerization,
fibrillization, and membrane-binding properties of monomeric
WT -syn to those of the phosphorylationmimics (S87E) as well
as the purified in vitro S87-phosphorylated form of -syn using
NMR, CD, SEC, SDS-PAGE, ThT, and transmission EM (TEM).
Phosphorylation at S87 is sufficient to block -syn fibrillization
Recent studies from our laboratory demonstrated that CK1-
mediatedphosphorylationblocks-syn fibrillization (Paleologou et
al., 2008). In vitroCK1 phosphorylation ofWT-syn followed by
tryptic digestion and mapping of phos-
phorylation sites revealed that CK1 phos-
phorylates -syn at multiple sites (S87,
T92, S129), with S87 and S129 being the
major phosphorylation sites (supplemen-
tal Figs. 2, 3, available at www.jneurosci.
org as supplemental material). To deter-
mine the relative contributions of phos-
phorylation at S87 to the CK1-induced
inhibition of -syn fibril formation, we ex-
amined the effect of CK1-mediated phos-
phorylation on the fibrillization of the
S129A and S129E, both of which cannot be
phosphorylated at S129. Prephosphoryla-
tionof both variantswithCK1 results in sig-
nificant retardation of -syn fibrillization
and a reduction in amyloid fibril formation
relative to the unphosphorylated forms of
both proteins (supplemental Fig. 3, avail-
able at www.jneurosci.org as supplemental
material). S129A, S129E, and theWT-syn
formed significant amounts of amyloid
fibrils, whereas prephosphorylated forms of
S129E(S129E/S87P)andWT(S129P/S87P)
showed predominantly soluble oligo-
meric species. S129A rapidly forms
short protofibrillar/fibrillar structures,
consistent with its marked increased pro-
pensity to fibrillize (Paleologou et al., 2008).
However, the amount of fibrils formed by
prephosphorylated S129A is significantly
less than that observed for unphosphory-
lated S129A.
To further prove that inhibition of
-syn fibrillogenesis is due to phosphory-
lation at S87, we prepared and purified the
S87-P phosphorylated forms of S129A
and S129E -syn and compared their aggregation properties to
those of the corresponding unphosphorylated forms of -syn.
The phosphorylated (S87-P) and unphosphorylated -syn forms
of each protein were separated by RP-HPLC and their purities
were verified by MALDI-TOF mass spectrometry. We consis-
tently observed that the mono (S87-P) and diphosphorylated
(S87-P/ T92-P) forms of S129A and S129E species did not form
fibrils even after 48 h, whereas the unphosphorylated forms of
these proteins exhibited extensive fibril formation after 24 h of
incubation (Fig. 7A). These observations were confirmed by SEC
and TEM studies, which revealed the absence of any fibrillar ag-
gregates and presence of predominantlymonomers in the S129A/
S87-P and S129E/S87-P samples (Fig. 7B,C). Interestingly,
monophosphorylated S129E/S87-P appears to form significantly
less oligomeric/protofibrillar-like aggregates than S129A/S87-P,
suggesting that the presence of both phosphate and Glu substitu-
tions at S87 and S129, respectively results in a greater inhibition
of -syn fibrillization.
In the fibrillar state, only S129 undergoes phosphorylation by CK1
in vitro
According to the solid state NMR data -syn residue 87 is in a
region that is part of the rigid structure of the fibrils and within
one of the -strands participating in the formation of the fibril
structure (Kloepper et al., 2007; Heise et al., 2008; Vilar et al.,
2008), suggesting that it might not be subject to phosphorylation
Figure 6. Colocalization of S87-P and CK1within inclusions in the thy1--syn TGmice and LBD/PD diseased brains. Vibratome
sections (40 m thick) from -syn TG mice and LDB/PD cases were stained against S87-P and CK1. A, B, A representative
immunostaining from the temporal cortex demonstrates a great degree of colocalization of S87-P and CK1 in thy1--syn TGmice
inclusions (A) and LBD/PD LB-like structure (B), compared to the controls.
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after fibril formation has occurred. To de-
termine whether S87 is accessible and can
undergo phosphorylation in the fibrillar
state, we generated monomer-free fibril-
lar samples of WT -syn and subjected
them to in vitro phosphorylation with
CK1. Phosphorylation was assessed by
Western blotting using antibodies against
-syn, S87-P, and S129-P. We observed
that only S129 undergoes phosphoryla-
tion by CK1, suggesting that S87, within
-syn fibrils, is not accessible or exists in a
conformation that is not recognized by
CK1 (supplemental Fig. 5, available at
www.jneurosci.org as supplemental
material).
The phosphomimic S87E aggregates slower
than WT and S87A -Syn
Selective phosphorylation and/or overex-
pression of S87-P in vivo is currently not
possible, as CKI phosphorylates at both
S87 and S129 and DYRK1A-mediated
phosphorylation at S87 is less efficient.
Therefore, future efforts to assess the role
of S87 phosphorylation inmodulating the
normal biology and aggregation of -syn
in vivo are likely to rely on the use of the
phosphomimics S87E and S87A. Recent
studies from our group (Paleologou et al.,
2008) and others (Waxman and Giasson,
2008;McFarland et al., 2009) demonstrate
that substitution of S129 by glutamate or
aspartate does not reproduce the effect of
phosphorylation at this site on -syn
structure and aggregation properties in
vitro. Having established that S87-P is suf-
ficient to inhibit -syn oligomerization
and fibrillogenesis, the 87 mutants S87A
and S87E were generated to assess whether
the phosphorylation mimic S87E is likely
to mimic S87 phosphorylation in vivo.
Comparison of the fibrillization of WT,
S87A, and S87E -syn showed that S87A
aggregated at a similar rate and to similar levels as WT -syn,
whereas for S87E the observed aggregation rate was slower than
those of the WT and S87A proteins (Fig. 7D). TEM images fur-
ther confirmed these findings, as both WT and S87A formed
dense networks of fibrils as opposed to S87E, which formed a
few short fibrils after 72 h of aggregation (Fig. 7F ). In accor-
dance with these findings, the consumption of monomeric pro-
tein over time monitored by SEC and SDS-PAGE analysis also
revealed a significant decrease in monomeric WT and S87A (Fig.
7B,E), whereas the levels of themonomeric S87E-syn remained
virtually unchanged over the 72 h of aggregation, providing fur-
ther evidence that S87E does not aggregate.
-Syn is disordered independent of phosphorylation at S87
Serine 87 lies in the hydrophobic NAC region of -syn, suggest-
ing that the introduction of a negative charge through the substi-
tution of serine by glutamate at this position is unfavorable and
may alter the secondary structure and hydrodynamic properties
of monomeric -syn. Figure 8A demonstrates that WT, S87A,
and S87E -syn exhibit virtually identical random coil and
-helical CD spectra in solution and upon binding to synthetic
membranes, respectively. Given that -syn exists predominantly
in a random coil conformation, subtle changes in the secondary
structure of the protein are unlikely to be discernible by CD stud-
ies. Therefore, to further elucidate the consequences of phos-
phorylation on the structure and dynamics of monomeric -syn,
high-resolution NMR studies were also conducted. For all pro-
teins, the resonances in 1H-15N HSQC spectra were sharp and
showed only a limited dispersion of chemical shifts, reflecting a
high degree of backbone mobility (Fig. 8B). After phosphoryla-
tion of WT -syn by CK1, the resonances of S87 and S129 were
strongly attenuated at the position seen in the proton-nitrogen
correlation (HSQC) of the unphosphorylated protein, but new
signals appeared in the region, in which resonances of phosphor-
ylated amino acids are usually found (supplemental Fig. 4A,
available at www.jneurosci.org as supplemental material). For
S129D -syn, phosphorylation at S129 was blocked so that only
the resonance of S87 was attenuated at its original position and
Figure7. Phosphorylationat S87 inhibits S129A-synaggregationpropensity.A, ThT fluorescencewasmonitoredat indicated
time points from samples of 70M solutions ofWT, S129A, S129A/S87-P, and S129A/S87-P, T92-P S87E-syn incubated at 37°C.
B, The samples were collected at the indicated time points and centrifuged at 18,000 g for 30min at 4°C before their superna-
tants were separated on a 12% SDS gel or applied to an analytical Superedex 200 PC 3.2/30 column. The analysis was carried out
under isocratic conditions (10mMTris, pH7.4) and the signalwasmonitoredat 280nm.C, Negatively stainedTEM imagesof S129A,
S129A/S87-P, andS129A/S87-P, T92-PS87E-synafter 96hof incubationat37°Cunder agitating conditions (Scalesbar, 200nm).
D–F, Assessing and comparing the aggregation propensity of WT, S87A, and S87E-syn. D, ThT fluorescence was monitored at
indicated time points from samples of 60 M solutions of WT, S87A, and S87E -syn incubated at 37°C. E, The samples were
collected at the indicated timepoints and centrifuged at 18,000g for 30min at 4°C before their supernatantswere separated on
a 12% SDS gel (F ) or applied to an analytical Superedex 200 PC 3.2/30 column. The analysis was carried out under isocratic
conditions (10mM Tris, pH 7.4) and the signal wasmonitored at 280 nm. F, Negatively stained TEM images ofWT, S87A, and S87E
-syn after 0 h and 72 h of incubation at 37°C under agitating conditions (Scales bar 200 nm). Coomassie-stained gel of the
samples after 0 h and 72 h of aggregation.
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appeared at its phosphorylated position (Fig. 8B). Other chem-
ical shift changes induced by phosphorylation were generally
small. In addition, steady-state heteronuclear 15N[ 1H]-NOEs
(Fig. 8C), 15N R1 relaxation rates and
3J(HN,H) couplings
(supplemental Fig. 4, available at www.jneurosci.org as sup-
plemental material) were very similar for unphosphorylated
and phosphorylated -syn, indicating that phosphorylation at
S87 has no apparent effect on the secondary structure of
-syn.
Pulse field gradient NMR experiments allow accurate deter-
mination of the diffusion coefficient of a molecule. From the
diffusion coefficient, a hydrodynamic radius Rh can be calculated
that provides an estimation of the overall dimensions of a bi-
omolecule (Farrow et al., 1994). For WT and S129D -syn, we
determinedhydrodynamic radii of 28.2Å and 28.1Å, respectively
(Fig. 8D). The phosphorylation mimic S87E did not change the
hydrodynamic radius of -syn. On the other hand, phosphoryla-
tion of S129A and S129D-syn at S87 increasedRh by 2.6 and 1.9
Å (Fig. 8D). Addition of 8 M urea to phosphorylated S87A -syn
further increased the Rh value to 36.2 Å. If -syn were a true
random coil, a hydrodynamic radius of 36.9 Åwould be expected
(Kohn et al., 2004). Interestingly, phosphorylation of S129 ap-
pears to have amore dramatic effect on the hydrodynamic radius
of monomeric -syn as it results in an increase of Rh by5.0 Å.
This result is consistent with our previous studies demonstrating
disruption of the intramolecular interactions between the C- and
N-terminal regions of -syn upon phosphorylation at S129 and
suggest that phosphorylation at S87 may only partially disrupt
this interaction (Paleologou et al., 2008).
Phosphorylation at S87 results in
changes in protein conformation upon
membrane binding
In the presence of SDS micelles, the lipid-
binding domain of-syn adopts a confor-
mation consisting of twohelical segments,
which have been previously characterized
using NMR (Eliezer et al., 2001; Bussell
and Eliezer, 2003; Chandra et al., 2003;
Ulmer and Bax, 2005). A comparison of
proton-nitrogen correlation spectra of
micelle-bound phosphorylated WT (S87-P
and S129-P) -syn and its unphosphory-
lated counterpart shows that the resonances
of S87 and S129 of the phosphorylated pro-
tein are dramatically shifted. In addition to
local changes, many resonances of amino
acids in the vicinity of S87-P were also
shifted (79, 81, 83, 84, 85, 86, 88, 89, 91, 92,
93, 94, 95, 96) (Fig. 9A). Most of these
amino acids are part of the secondhelix that
-syn adopts upon binding tomicelles. Rel-
atively less extensive shifts were observed in
the resonances of amino acids close to S129,
consistent with our previous studies of the
effects of phosphorylation at this site (Pale-
ologou et al., 2008). Similar changes in the
vicinity of S87-P were made when compar-
ing the HSQC spectra of S129A/S87-P (Fig.
9B) and S129E/S87-P (Fig. 9C) and their
unphosphorylated counterparts, strongly
suggesting that changes occur in the envi-
ronment of the second helix are a result of
S87 phosphorylation.
To quantify the chemical shift changes between the phosphor-
ylated and unphosphorylated micelle-bound proteins, the reso-
nances of each form of S129A -syn were directly assigned using
triple resonance methods. Graphs of the resulting weighted aver-
age of the amide proton and nitrogen chemical shift changes
between the phosphorylated and unphosphorylated proteins are
shown (Fig. 9E) for S129A /S129A-S87-P. A similar graph was
generated for S129E/S129E-S87-P (Fig. 9F) by transferring the
S129A assignments. The data demonstrate clearly that relatively
large chemical shift changes take place at sites close to S87 in
both phosphorylated proteins, with more minor changes
spanning the region between residues 60 and 80. Chemical
shift changes observed upon comparing micelle-bound un-
phosphorylated S129A or S129E with WT -syn were re-
stricted to the immediate sites of the mutation and were
essentially identical to those previously observed for the free
protein (Paleologou et al., 2008), indicating that the muta-
tions themselves do not cause long-range effects.
To better understand the effects of S87 phosphorylation on
the micelle-bound structure of -syn, we analyzed both sequen-
tialHN-HNNOEandC chemical shift data. TheNOEdata (Fig.
10A) reveal a decrease in signal intensity, when compared with
those previously obtained for the WT protein, in the second half
of the second micelle-bound helix, coinciding with the location
of the phosphorylated S87 residue and suggesting a possible de-
crease in the stability of the helical structure in this region. Ac-
cordingly, secondary C chemical shift data (Fig. 10B) also show
smaller positive amplitudes in this region when compared with
previous observations for the unphosphorylatedWT protein. In-
Figure8. -syn is disordered independentofphosphorylationat S87.A, Circular dichroismspectroscopy reveals thatWT (blue),
S87A (red), and S87E (green) -syn adopt random coil structure. -Syn at 10M. B, Comparison of two-dimensional 1H- 15N
HSQC spectra of nonphosphorylated S129D -syn (blue) and phosphorylated S129D -syn (red). Resonance assignments are
indicatedwith residue numbers. A dashed rectanglemarks glutamine and asparagine side chain resonances. C, Heteronuclear 15N
[ 1H]-NOEs in nonphosphorylated WT -syn (black), phosphorylated WT -syn (gray), and phosphorylated S129D -syn (red).
D, Hydrodynamic radii of various -syn mutants in phosphate buffer at 15°C with and without 8 M urea. In phosphorylated
S129A/D-syn, only S87 was phosphorylated.
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terestingly, these structural effects are
similar to those observed for the protein
-syn, a close homolog of -syn, which is
however missing 11 residues from the
NAC region (Sung and Eliezer, 2006,
2007).
To further probe the effect of phos-
phorylation on -syn-membrane inter-
actions, we compared the CD spectra of
mono- (S129A/S87-P) and diphosphory-
lated S129A (S129A/S87-P,T92-P) to that
of S129A and WT -syn in solution and
upon binding to POPG vesicles. Although
the effect of phosphorylation at S87 andT92
at the monomer is not discernible by Far-
UV/CD (Fig. 10C), both mono- (S129A/
S87-P) and diphosphorylated (S129A/S87-
P,T92-P)exhibit reduced-helicalpropensity





occurs in vivo and is increased
in synucleinopathies
Phosphorylation is an important revers-
ible post-translational modification that
regulates the structural and functional
properties of proteins in health and dis-
ease. The role of phosphorylation inmod-
ulating the aggregation and fibrillogenesis
of tau and -syn is currently a subject of
intense investigation and pathways in-
volved are being pursued as viable targets
to prevent or slow down the progression
of AD and PD (Glicksman et al., 2007;
Wen et al., 2008; Rezai-Zadeh et al., 2008).
While hyperphosphorylation of tau at dif-
ferent sites has been well characterized
and the role of tau phosphorylation in AD
pathology was investigated in several
mouse models of AD, a thorough map-
ping and investigation of all phosphorylation sites within -syn
and of the kinases involved remains to be accomplished. Several
kinases phosphorylate -syn at S129 (Okochi et al., 2000; Pronin
et al., 2000; Fujiwara et al., 2002; Takahashi et al., 2003a; Chen
and Feany, 2005; Kim et al., 2006; Qing et al., 2009; Inglis et al.,
2009; Mbefo et al., 2010) and S87 (Okochi et al., 2000; Pronin et
al., 2000), as well as Y125 (Ellis et al., 2001; Nakamura et al., 2001;
Hasegawa et al., 2002; Takahashi et al., 2003a), Y133 (Ellis et al.,
2001; Negro et al., 2002), and Y136 (Ellis et al., 2001; Negro et al.,
2002) in vitro. However, only phosphorylation at S129 has been
shown to correlate with the pathology of PD and related
-synucleinopathies. Here we demonstrate that -syn is phos-
phorylated at S87 in vivo and the level of S87-P is increased in
brains of TG models of synucleinopathies and human brains
from AD, LBD, and MSA patients. To determine whether -syn
in LBs is also phosphorylated at S87, we performed immunoflu-
orescence stainings of LBs isolated from fresh human brains us-
ing our anti-S87-P antibody. S87-P immunoreactivity was
consistently detected in homogeneous presumably earlier stages
of formation as well as mature LBs, suggesting S87-P -syn oc-
curs throughout the life span of LB development.
Neither S87 nor S129 phosphorylation are found in LB, but
they are not responsible for LB formation
Previous studies from our group and others demonstrated that
phosphorylation at S129 blocks, rather than inhibit -syn fibril-
lization. Herein, we show that phosphorylation at S87 also inhib-
its -syn fibrillization in vitro. Together, these findings suggest
that phosphorylation at these residues should inhibit, rather than
promote LB formation in vivo. Our findings that S129, but not
S87, undergoes phosphorylation by CK1 in the fibrillar state is
consistent with the solid state NMR results and favor the hypoth-
esis that phosphorylation at S129 is a late event that occurs after
-syn fibrillization and/or during the development and matura-
tion of LBs. The increased level of S129-P is consistent with its
being further away from the core of the fibrils and in a region that
is highly disordered and thusmore accessible to phosphorylation
by kinases. The colocalization of several kinases (Arawaka et al.,
2006; Ryu et al., 2008) and -syn within LBs combined with
Figure 9. Phosphorylation at S87 results in changes in protein conformation upon membrane binding. A–C, Overlaid contour
plots of 1H- 15NHSQC spectra ofmonophosphorylatedWT (black) and its unphosphorylated control (red;A),monophosphorylated
S129A (black) and its unphosphorylated control (red;B), andmonophosphorylatedS129E (black) and its unphosphorylated control
(C). Amino acid residues that shift with respect to unphosphorylated proteins are labeled. D–F, Mean weighted 1H- 15N chemical
shift differences [calculated as [( 1H)	 ( 15N) 2/25] 1/2/2] between WT and S129A -syn in the SDS-bound state (D),
unphosphorylated S129A and S129A/S87-P in the SDS-bound state (E), and unphosphorylated S129E and S129E/S87-P in the
SDS-bound state (F ).
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recent studies from our group (Mbefo et al., 2010) and by Wax-
man and Giasson (2008) demonstrating that aggregated -syn
species are better substrate for CK1, CK2, and the PLK 1–3 sug-
gest that S129 phosphorylation could easily occur subsequent to
LB formation. When combined with our own observations that
S129 phosphorylation actually inhibits -syn fibrillization [also
confirmed by a recent study by Waxman and Giasson (2008)],
these observations provide strong support for the hypothesis that
phosphorylation at S129 is in fact not a prerequisite for LB
formation and more likely occurs after -syn fibrillization
(Fig. 10B).
Recent studies by Fournier et al. (2009), using our anti-S87-P
antibody, demonstrated that S87-P was only observed in the TBS
soluble fractions, whereas S129-P was observed in both soluble
and SDS fractions from healthy and symptomatic mice overex-
pressing-syn or-syn and Parkin. These results combined with
the presence of S87 in a-strand conformationwithin the core of
fibrils are consistent with our results showing the inhibition of
-syn fibrillization upon phosphorylation of this site and the lack
of phosphorylation in the preformed fibrillar state, but do not
explain how this residue becomes phosphorylated within LBs.
These observations could be explained if -syn within LBs exists
in different aggregated and/or fibrillar states, some of which may
possess different core-structure than-syn fibrils formed in vitro.
From the Lewy body data we have gathered, it appears that s87P
has been incorporated in Lewy bodies at early (with homoge-
neous morphology) as well as later
(concentric morphology) stages of matu-
ration. Alternately, the Lewy bodies we
typically observe may perhaps reflect later
events of the disease process and are likely
generated from small -syn aggregates
originating in sites where -syn turnover
is most active, for instance at synapses.
Small -syn aggregates may be retro-
gradely transported through axons, some-
times leading to the formation of Lewy
neurites. We did not detect S87-P in Lewy
neurites, suggesting that S87 phosphory-
lation is indeed a later event occurring af-
ter the formation of early aggregates.
Thus, S87 phosphorylation may occur
subsequent to early -syn aggregation,
but before the formation of the mature
amyloid fibril form, in which S87 is no
longer accessible to the responsible ki-
nases. Further studies will be required to
determine the aggregation states of S87-P
immunoreactive material within LBs and
to determine the kinetics of, and interplay
between, S87 and S129 phosphorylation
during the evolution of LBs.
S3 Emutation at S87 or S129 mimic
only some aspects of phosphorylation
Recent studies by two independent re-
search groups demonstrated that AAV-
mediated overexpression of the S129A in
the substantia nigra of rats results in both
increased aggregation and loss of dopami-
nergic neurons relative to overexpression
ofWTand S129D-syn (Gorbatyuk et al.,
2008; Azeredo da Silveira et al., 2009).
Thus, it appears that the increased in vivo aggregation caused by
the S129A mutation (which also promotes -syn aggregation in
vitro)may lead to toxicity that is unrelated to its effect in blocking
phosphorylation at S129. To properly probe the role of phos-
phorylation in vivo it is essential that mutants designed to abolish
phosphorylation should exhibit aggregation properties similar to
that of the WT protein. Similarly, phosphorylation mimicking
mutations should reproduce the structural and functional conse-
quences of -syn phosphorylation. Neither the S129A nor
S129D/E mutants fulfill these criteria as demonstrated by both
the in vivo studies cited above and our own recent in vitro studies.
In contrast, as we show here, the S87A and S87E mutants come
closer to fulfilling these criteria. Figure 7 demonstrates that S87A
exhibits similar fibrillization properties as the WT protein, whereas
S87E does not form fibrils, suggesting S 3 E substitution at S87
reproduces the effect of phosphorylation on -syn aggregation.
Together, these findings suggest that overexpression of S87E and
S87Amutants should facilitate the elucidation of the role of phos-
phorylating this residue on modulating -syn oligomerization
and fibrillogenesis in vivo.
Nevertheless, the fact that phosphorylation at S87 (S87-P),
but not the phosphomimic S87E, induced significant changes in
the conformation ofmembrane bound-syn that coincidedwith
a slight reduction in the propensity of S87-P to form -helical
structure during binding to membranes, suggests that S87E may
not recapitulate phosphorylation-dependent protein-membrane
Figure10. The effects of S87phosphorylation on themicelle-bound structure of-syn.A,B, Sequential amideprotonNOEs (A)
and  carbon secondary shifts (B) for SDS micelle bound S129A/S87-P -syn. NOEs represent the average of the forward and
backward crosspeak intensities between resonances originating from any two consecutive residues. Black bars show data previ-
ously reported for the unphosphorylatedWTprotein (Bussell and Eliezer, 2003),whereas blue bars represent the S87-P formof the
protein. Green bars represent regions of resonance overlap that preclude reliable detection of the presence or absence of an NOE
signal. Secondary shifts were calculated using NMRView (Delaglio et al., 1995) based on random coil shifts determined for small
peptides in 1 M urea at pH 5.0 (Wishart et al., 1995). C, Circular dichroism spectroscopy reveals that WT (yellow line), S129A (red
line), S129A/S87-P (green line), and S129A/S87-P, T92-P (blue line) -syn adopt random coil structure. -Syn at 10 M.
D, Circular dichroism spectroscopy of WT (yellow line), S129A (red line), and S129A/S87-P (green line), S129A/S87-P, T92-P (blue
line)-syn in the presence of POPG vesicles.-syn: POPG mass ratio is 1:20.
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interactions. Our findings demonstrate that detailed and careful
biophysical characterization of the phosphorylated proteins and
their phosphomimics can assist in designing and interpreting in
vivo studies aimed at elucidating the role of phosphorylation in
health and disease.
Potential role of S87 and S129 in regulating phosphorylation
dependent protein-protein interactions
Phosphorylation of proteins represents an important molecular
switch for regulating protein-protein and protein-ligand interac-
tions and thus protein function. The C-terminal region of -syn
has been implicated in the majority of -syn interactions with
proteins (Jensen et al., 1999; Giasson et al., 2003; Ferna´ndez et al.,
2004) and metal ions (Paik et al., 1999; Brown, 2007), and
phosphorylation in this region is likely to influence the affinity
of -syn for other proteins and thereby alter the biochemical
and biological processes regulated by its interactions. Indeed,
McFarland et al. recently showed differences in the set of pro-
teins pulled down by S129- or Y125-phosphorylated forms of
-syn (McFarland et al., 2008).
S87 lies in theNAC region, which is crucial inmediating-syn
fibrillization, and our results accordingly demonstrate that S87
phosphorylation exerts a profound effect on -syn aggregation.
Interestingly, our results also show that S87 phosphorylation al-
ters the conformation of membrane bound -syn and decreases
its affinity to lipid vesicles (Fig. 10), probably by destabilizing the
helical conformation and decreasing the lipid-binding affinity of
the protein around the phosphorylation site (Figs. 9, 10). S87 is
also located in a region involved in the interactions of -syn with
at least some proteins, such as the enzyme PLD2 (Payton et al.,
2004). Thus, phosphorylation at position S87 may offer fur-
ther opportunities, beyond phosphorylation in the C-terminal
tail region, for regulating synuclein protein-protein, as well as
protein-membrane interactions. Further studies of the effects
of S87 phosphorylation in vivo will be required to evaluate this
hypothesis.
Conclusions
The results presented here indicate that phosphorylation of-syn
at S87 clearly occurs in vivo and is increased in synucleinopathies.
However, the role of -syn S87 phosphorylation in disease is
unlikely to encompass directly increasing the fibrillization or
deposition of the protein as phosphorylation at this residue
blocks rather than promotes -syn fibrillization. Whether phos-
phorylation enhances or protects against -syn toxicity in vivo
remains controversial. Previous studies aimed at addressing this
question in the case of S129 phosphorylation are based on over-
expression of the phosphomimics (S129E /D), which do not re-
produce all aspects of phosphorylation and have yielded
contradictory results (Chen and Feany 2005; Gorbatyuk et al.,
2008; Azezredo da Silveira et al., 2009; McFarland et al., 2009).
Our work here suggests that S87E should provide a more robust
phosphomimic, at least as regards its effects on a-syn aggregation.
To date, emphasis has been placed on trying to elucidate the role
of phosphorylation in modulating -syn aggregation and toxic-
ity. However, -syn phosphorylation at S87 may also influence
the normal function of the protein, either by perturbing the
membrane-bound conformation of the protein as suggested by
our data, or by modulating protein-protein interactions, as has
been shownpreviously for other phosphorylation sites. The iden-
tification of the natural kinases and phosphatases involved in
regulating-syn phosphorylation at S87 (and S129) should facil-
itate studies of its effects on both synuclein toxicity and function
and is of crucial importance both to understanding the role of
phosphorylation in the pathogenesis of PD and to the identifica-
tion of novel targets to treat PD and related synucleinopathies.
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